Catalent, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTLT research report →
Companywww.catalent.com
Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- CEO
- Alessandro Maselli
- IPO
- 2014
- Employees
- 17,000
- HQ
- Somerset, NJ, US
Price Chart
Valuation
- Market Cap
- $11.52B
- P/E
- -11.02
- P/S
- 2.63
- P/B
- 3.19
- EV/EBITDA
- -56.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 21.75%
- Op Margin
- -17.10%
- Net Margin
- -23.81%
- ROE
- -25.32%
- ROIC
- -8.53%
Growth & Income
- Revenue
- $4.38B · 2.46%
- Net Income
- $-1,043,000,000 · -349.57%
- EPS
- $-5.76 · -350.00%
- Op Income
- $-749,000,000
- FCF YoY
- 81.68%
Performance & Tape
- 52W High
- $63.50
- 52W Low
- $42.11
- 50D MA
- $60.41
- 200D MA
- $58.22
- Beta
- 1.16
- Avg Volume
- 2.27M
Get TickerSpark's AI analysis on CTLT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 18, 24 | Gennadios Aristippos | other | 21,562 |
| Dec 18, 24 | Gennadios Aristippos | sell | 21,562 |
| Dec 18, 24 | McErlane David | other | 11,426 |
| Dec 18, 24 | McErlane David | sell | 14,740 |
| Dec 18, 24 | McErlane David | sell | 11,426 |
| Dec 18, 24 | Hatzfeld Michael | other | 3,144 |
| Dec 18, 24 | Hatzfeld Michael | sell | 3,144 |
| Dec 18, 24 | Gunther Scott | other | 12,938 |
| Dec 18, 24 | Gunther Scott | sell | 12,938 |
| Dec 18, 24 | Ferraro Joseph Anthony | other | 14,265 |
Our CTLT Coverage
We haven't published any research on CTLT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CTLT Report →